Meeting
2018 Gastrointestinal Cancers Symposium
Clinical outcomes of FOLFIRINOX and gemcitabine/nab-paclitaxel in the real world setting.
Authors
Fernando Franco Franco
Puerta de Hierro Majadahonda University Hospital, Madrid, Spain
Fernando Franco Franco , Camara Juan C , Jose Ignacio Martin Valades , David Marrupe , David Gutierrez Abad , Ana Leon , Ignacio Juez , Maria Victoria De Torres , Antonio Carlos Sánchez-Ruiz , Elsa Bernal , Silvia Garcia Adrian , Diana Moreno , Ana Cardena , Roberto Hernández , Ana Ruiz-Casado
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 440)
DOI
10.1200/JCO.2018.36.4_suppl.440
Abstract #
440
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
First Author: Aaron Ciner
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Depth of response in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory subgroup analysis of JCOG1407.
First Author: Taro Shibuki
Poster
2018 Gastrointestinal Cancers Symposium
The relationship between dose to skeletal muscle area ratio and gemcitabine nab-paclitaxel toxicity in pancreatic ductal adenocarcinoma.
First Author: Rachel Wong
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang